William D. Waddill
Known title: DirectorCIK: 0001553338
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Transaction History
| PTGX | ▲ Buy | Option Exercise | 9,000 | $149K | 6/23/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 9,000 | $1.1M | 6/23/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 3,000 | $35K | 6/10/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 6,000 | $99K | 6/10/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 9,000 | $969K | 6/10/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 9,000 | $106K | 5/29/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 9,000 | $897K | 5/29/2026 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 20,000 | $166K | 2/6/2026 | View on chart |
| PTGX | ▼ Sell | Open Market | 20,000 | $1.7M | 2/6/2026 | View on chart |
| PTGX | ▲ Buy | Grant | 2,695 | $0 | 1/2/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,416 | $161K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 5,451 | $371K | 12/19/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 500 | $34K | 12/19/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 7,819 | $0 | 12/16/2025 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 12,000 | $84K | 10/10/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 4,000 | $277K | 10/10/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 8,000 | $702K | 10/10/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 4,000 | $257K | 9/22/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 4,000 | $237K | 8/27/2025 | View on chart |
| PTGX | ▼ Sell | Open Market | 4,000 | $217K | 3/17/2025 | View on chart |
| PTGX | ▲ Buy | Grant | 5,130 | $0 | 1/2/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 16,733 | $385K | 12/18/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,747 | $83K | 12/17/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,748 | $82K | 12/16/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 8,000 | $103K | 9/10/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 8,000 | $360K | 9/10/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 8,000 | $103K | 7/24/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 8,000 | $320K | 7/24/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 8,000 | $103K | 6/7/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 8,000 | $280K | 6/7/2024 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 12,975 | $79K | 3/1/2024 | View on chart |
| PTGX | ▼ Sell | Open Market | 12,975 | $407K | 3/1/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,634 | $100K | 1/11/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,300 | $50K | 1/11/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,200 | $96K | 1/9/2023 | View on chart |
| PTGX | ▲ Buy | Option Exercise | 12,000 | $103K | 5/3/2022 | View on chart |
| ARWR | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,100 | $135K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,128 | $138K | 1/3/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 272 | $18K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
PTGX featured in recent SeekingAlpha and Benzinga articles
A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.
PTGX featured in recent SeekingAlpha and Benzinga articles. A SeekingAlpha column noted Johnson & Johnson’s strong catalysts while keeping a hold stance, a view that may influence sentiment toward biotech peers such as Protagonist Therapeutics. Separately, Benzinga published a piece examining how a $100 investment in PTGX ten years ago would have grown, highlighting the stock’s historical performance. These mentions reflect ongoing analyst and investor interest in the company.